ValiRx Regulatory News (VAL)

19 January 2021

("ValiRx", the "Company" or the "Group")

Director Disclosure

London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, announces that Martin Lampshire, Non-Executive Director of the Company, has advised ValiRx that, on 21 December 2020, the creditors of Global Resources Investment Trust PLC, of which he is a director, approved a Company Voluntary Arrangement.

This announcement is made in accordance with Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Ends

For further information please contact:

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/